The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Essential Hypertension

Essential Hypertension

Essential hypertension is a common condition characterized by persistently elevated blood pressure without an identifiable underlying cause.
It is a major risk factor for cardiovascular disease, stroke, and kidney damage.
Researchers can leverage AI-powered tools like PubCompare.ai to streamline their essential hypertension studies.
This platform helps locate relevant protocols from literature, preprints, and patents, and provides AI-driven comparisons to identify the best research approaches.
By enhancing reproducibility and acuracy, PubCompare.ai can be the ultimate tool for your essential hypertension research needs.

Most cited protocols related to «Essential Hypertension»

In addition to identifying a cause list and mapping this cause list across various revisions of the ICD, the largest impediment to comparability is the presence of a different set of GCs in each ICD revision. To more fully understand the problem of garbage codes, we created a typology of these codes that distinguishes four types of GCs. This typology has been developed taking into consideration the following: the likelihood that a condition can be an underlying cause of death; the need for codes that provide a location for unspecified or ambiguous causes of death; and the need for codes that represent causes that are not underlying but intermediate or final events in the chain leading to death. Four categories were identified:
1. Causes that cannot or should not be considered as underlying causes of death. These are codes that are included in the ICD because of its use for classifying health service encounters but that do not signify underlying cause of death. Examples of this type of GC are all the codes under chapter 18 of ICD-10 or R codes. This category also includes two special cases in the cardiovascular area: essential primary hypertension and atherosclerosis. Essential primary hypertension is included in the ICD to classify clinical encounters, but for most physicians, it should be considered a risk factor for cardiovascular disease and not the underlying cause. This distinction between what is a risk factor and what is an underlying cause is somewhat arbitrary but necessary to enhance comparability across revisions. Finally, we included in this category a number of causes that are described as the long-term sequelae of disease, such as G82, paraplegia and tetraplegia, or O94, sequelae of complication of pregnancy, childbirth, and the puerperium. In these cases, for public health purposes, it is more useful to assign these deaths to the underlying cause despite the long time lag between disease and death.
2. Intermediate causes of death such as heart failure, septicemia, peritonitis, osteomyelitis, or pulmonary embolism. These are clearly defined clinical entities, but each has an underlying cause that would have precipitated the chain of events leading to death. Physicians who have not been adequately trained in the principles of the ICD underlying cause of death often use these causes on death certificates.
3. Immediate causes of death that are the final steps in a disease pathway leading to death. Examples of this include disseminated intravascular coagulation or defibrination syndrome (D65). The pathway to death includes the final immediate cause, an intermediate cause, and the underlying cause that triggered the chain of events. Cardiac arrest (I46) and respiratory failure, not elsewhere classified (J96), are other examples.
4. Unspecified causes within a larger cause grouping. For many diseases, such as neoplasms, a code is included within the grouping for an unspecified site. This is an illustration of a GC that is not important for assessing aggregate deaths from neoplasms from all sites but is important when assessing site-specific death rates. Another important example is the injury category in which some injuries are coded to unspecified factors or intent.
Table 2 provides a listing of the number of each type of GC that we identified related to our 56-cause list. The largest category of GCs is type 1. Assessment of the number of GCs, especially in category 4, is a function of the level of detail in the final cause list that is being developed.
Full text: Click here
Publication 2010
Atherosclerosis Cardiac Arrest Cardiovascular System Congestive Heart Failure Disseminated Intravascular Coagulation Essential Hypertension Garbage Injuries Neoplasms Neoplasms by Site Obstetric Delivery Osteomyelitis Paraplegia Peritonitis Physicians Pregnancy Complications Pulmonary Embolism Quadriplegia Respiratory Failure Septicemia sequels
We extracted ICD-10-CM codes from the 2018AA release of the UMLS [18 ] and used several automated methods to translate ICD-10-CM diagnosis codes to phecodes (Figure 1). We mapped 515 ICD-10-CM codes directly to phecodes by matching code descriptions regardless of capitalization (eg, ICD-10-CM H52.4 “Presbyopia” to phecode 367.4 “Presbyopia”). We mapped 82,287 ICD-10-CM codes indirectly to phecodes using the existing ICD-9-CM phecode map [14 ]. To convert ICD-10-CM codes indirectly to phecodes, we used General Equivalence Mappings (GEMS) provided by the Centers for Medicare & Medicaid Services that map ICD-10-CM to ICD-9-CM and vice versa [22 ]. We included both equivalent and nonequivalent GEMS mappings (ie, where the approximate flag was either 0 or 1). As an example of this indirect approach, to map ICD-10-CM E11.9 “Type 2 diabetes mellitus without complications” to phecode 250.2 “Type 2 diabetes,” we mapped ICD-10-CM E11.9 to ICD-9-CM 250.0 “Diabetes mellitus without mention of complication” to phecode 250.2.
Since the GEMS do not provide ICD-9-CM mappings for all ICD-10-CM codes [17 (link)], we complemented this approach with UMLS semantic mapping [24 (link)], Observational Health Data Sciences and Informatics (OHDSI) concept relationships [25 ,26 (link)], and National Library of Medicine (NLM) maps [23 ]. In this approach to indirect mapping, we first mapped ICD-10-CM codes to Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) through UMLS Concept Unique Identifier (CUI) equivalents, which were then converted to ICD-9-CM through either UMLS CUI equivalents [18 ,24 (link)], OHDSI [25 ], or NLM maps [23 ]. For example, we mapped ICD-10-CM L01.00 “Impetigo, unspecified” to CUI C0021099 to SNOMED CT 48277006 to OHDSI Concept ID 140480 to OHDSI Concept ID 44832600 to ICD-9-CM 684 and finally to phecode 686.2 “Impetigo”.
There were two general instances when an ICD-10-CM code mapped to more than one phecode. First, some ICD-10-CM codes mapped to both a parent phecode and one of its child phecodes that was lower in the hierarchy. To maintain the granular meanings of ICD-10-CM codes, we only kept the mappings to child phecodes, a decision that we could make due to the hierarchical structure of phecodes. For example, ICD-10-CM I10 “Essential (primary) hypertension” was mapped to phecodes 401 “Hypertension” and 401.1 “Essential hypertension”, but we only kept the mapping to phecode 401.1. Second, we kept all the mappings for ICD-10-CM codes that were translated to phecodes that were not in the same family. This can be seen in the mapping of ICD-10-CM D57.812 “Other sickle-cell disorders with splenic sequestration” to phecodes 282.5 “Sickle cell anemia” and 289.5 “Diseases of spleen”. This latter association created a polyhierarchical nature to phecodes that did not previously exist.
To map ICD-10 (non-CM) codes to phecodes, we also used ICD-10 codes from the 2018AA UMLS [18 ]. ICD-10 codes were mapped to phecodes in a similar manner to ICD-10-CM, but since a GEMS to translate ICD-10 to ICD-9-CM was not available, we used only string matching and previously manually reviewed resources from the UMLS [24 (link)], NLM [23 ], and OHDSI [25 ,26 (link)].
Full text: Click here
Publication 2019
Anemia, Sickle Cell Child Complications of Diabetes Mellitus Diabetes Mellitus Diabetes Mellitus, Non-Insulin-Dependent Diagnosis Essential Hypertension High Blood Pressures Impetigo Microtubule-Associated Proteins Parent Presbyopia Spleen Splenic Diseases Vision
The correspondence of the determined allele and genotype frequencies to Hardy–Weinberg equilibrium (HWE) was estimated with the chi-square test. The logistic regression approach with adjustment for covariates was applied to analyze associations of the genetic variants with XFG and POAG. The three standard genetic models were assumed: additive, recessive, and dominant. The following covariates were applied: age, body mass index (BMI), systolic and diastolic blood pressures as quantitative variables and a family history of glaucoma, the presence of essential hypertension, heart atherosclerosis, heart ischemia, and diabetes mellitus (either type I or type II) as qualitative variables (Table 1). Adjustment for multiple comparisons for several SNPs was performed using the adaptive permutation test [19 (link)], and that for the number of genetic models (three) and groups compared (three), using the Bonferroni correction. Thus, the aggregated level of significance was set at pperm<0.006 (0.05/9). Quanto 1.2.4 (Hydra 2009) was used to compute statistical power for each SNP.
The confidence intervals algorithm at D’>0.8 as implemented in HaploView v.4.2 was applied to identify haplotype blocks. Adjustment for multiple comparisons was performed using the permutation test (1,000 permutations). Taking account of the number of haplotypes studied (seven) and the number of cohorts (three), the aggregate significance level after the Bonferroni correction was set at pperm<0.0024 (0.05/21). The computations above were performed using the respective algorithms implemented in the gPLINK v. 2.050 software.
Publication 2021
Acclimatization Alleles Atherosclerosis Diabetes Mellitus Essential Hypertension Genetic Diversity Genotype Glaucoma Glaucoma, Primary Open Angle Haplotypes Heart Hydra Index, Body Mass Myocardial Ischemia Pressure, Diastolic Systole
Some variation in death rates for amenable causes are due to differences in behavioural and environmental risk exposure rather than differences in personal health-care access and quality.48 (link), 54 (link), 55 (link) Using the wide range of risk factors assessed by GBD,48 (link) we risk-standardised death rates to the global level of risk exposure.48 (link) We did not risk-standardise for variations in metabolic risk factors directly targeted by personal health care: systolic blood pressure, total cholesterol, and fasting plasma glucose. For example, stroke deaths due to high systolic blood pressure are amenable to primary care management of hypertension.
To risk-standardise death rates, we removed the joint effects of national behavioural and environmental risk levels calculated in GBD, and added back the global levels of risk exposure:
mrjascy=mjascy(1-JPAFjascy1-JPAFjasgy) where mjascy is the death rate from cause j in age a, sex s, location c, and year y; mrjascy is the risk-standardised death rate; JPAFjascy is the joint population attributable fraction (PAF) for cause j, in age a, sex s, country c, and year y for all behavioural and environmental risks included in GBD; and JPAFjasgy is the joint PAF for cause j, in age a, sex s, and year y at the global level.
GBD provides joint PAF estimation for multiple risks combined, which takes into account the mediation of different risks through each other. Further detail on joint PAF computation is available in the appendix (pp 5–8).
We used the GBD world population standard to calculate age-standardised risk-standardised death rates from each cause regarded as amenable to health care.47 (link) We did not risk-standardise death rates from diarrhoeal diseases as mortality attributable to unsafe water and sanitation was not computed for high-SDI locations; such standardisation could lead to higher risk-standardised death rates in those countries compared with countries where mortality was attributed to unsafe water and sanitation.48 (link) With all causes for which no PAFs are estimated in GBD, such as neonatal disorders and testicular cancer, risk-standardised death rates equalled observed death rates.
The effects of risk-standardisation are highlighted by comparing the log of age-standardised mortality rates to the log of age-standardised risk-standardised mortality rates for amenable causes (appendix p 14). For each SDI quintile, many countries had differing levels of age-standardised mortality rates but their risk-standardised mortality rates were similar, demonstrating how underlying local risk exposure can skew measures of mortality amenable to personal health care.
Full text: Click here
Publication 2017
Cerebrovascular Accident Cholesterol Diarrhea Environmental Exposure Essential Hypertension Glucose High Blood Pressures Joints Neonatal Diseases Plasma Population at Risk Systole Systolic Pressure Testicular Cancer
The study was approved by Ethical Review Committee of Kursk State Medical University. A total of 2 995 Russian unrelated subjects from Kursk (discovery cohort) and Belgorod (replication population) regions of Central Russia were included in the study. The discovery cohort comprising 2 216 subjects (1 362 EH patients and 843 healthy subjects with normal blood pressure) was recruited at Cardiology Clinics of Kursk Regional Clinical Hospital and Neurology Clinics of Kursk Emergency Medicine Hospital over two periods: between 2003 and 2006 [7 (link)] and between 2010 and 2013. The replication population included DNA samples from 779 individuals (357 EH patients and 422 population controls) which have been obtained from the biobank of Belgorod State National Research University, as part of a large population-based study of Belgorod region [8 (link)]. The baseline characteristics of the study patients are listed in Table 1. As can be seen from Table 1, hypertensive patients were matched to controls on sex and age (P > 0.05). Diagnosis of essential hypertension in both populations was verified by qualified cardiologists. Individuals were defined as hypertensive according to World Health Organization criteria or if they had a history of receiving any antihypertensive drug. Diagnosis of EH in untreated patients was defined by a seated systolic and/or diastolic blood pressure greater than 140 and/or 90 mmHg, respectively, on at least 2 separate measurements. All EH patients had no clinical signs, symptoms, and laboratory findings suggestive of secondary hypertension.
Genomic DNA was isolated from peripheral blood samples using a standard phenol/chloroform procedure. Genotyping of polymorphism E158K of the FMO3 gene was done using PCR followed by RFLP analysis as described elsewhere [9 ]. The genotyping results were scored by two independent investigators blindly to the patient's case/control status and regenotyping of about 5% of randomly selected samples yielded 100% reproducibility.
The association between the polymorphism and hypertension risk was estimated by odds ratio (OR) with 95% confidence interval (CI) using multiple logistic regression analysis with adjustment for confounding variables such as age and gender. Each FMO3 genotype was assessed according to dominant, recessive, and additive genetic models, and the chi-squire (Wald's statistic) odds ratio with 95% confidence interval was calculated. Odds ratios were calculated as a measure of the association of the FMO3 genotype with hypertension risk, with the effects of the allele 158K assumed to be additive (with scores of 0, 1, and 2 assigned for EE, EK, and KK genotypes, resp.), dominant (with scores of 0 for EE genotype and 1 for EK and KK genotypes combined), or recessive (with scores of 0 for EE and EK genotypes combined and 1 for KK genotype). The statistical significance was established at P ≤ 0.05. Bonferroni correction for P values (Padj) was applied in cases when multiple tests were performed. Statistical calculations were performed with Statistica for Windows 8.0 (StatSoft Inc., Tulsa, OK, USA).
Full text: Click here
Publication 2014
Alleles Antihypertensive Agents BLOOD Blood Pressure Cardiologists Cardiovascular System Chloroform Diagnosis DNA Replication Emergencies Essential Hypertension Ethical Review Gender Genetic Polymorphism Genome Genotype Healthy Volunteers High Blood Pressures Patients Phenols Population Group Pressure, Diastolic Respiratory Rate Restriction Fragment Length Polymorphism Systole Vision

Most recents protocols related to «Essential Hypertension»

Example 1

This section describes an example of the outcome of renal neuromodulation on human patients. A total of 45 patients (mean age of 58±9 years) diagnosed with essential hypertension were treated with percutaneous, catheter based renal nerve ablation. Treatment included RF energy delivery to the renal artery using a single-electrode Symplicity Flex™ catheter commercially available from Medtronic, Inc., of 710 Medtronic Parkway, Minneapolis, Minnesota 55432-5604. In this human trial, a radiotracer dilution method was used to assess overflow of norepinephrine from the kidneys into circulation before and 15-30 days after the procedure in 10 patients. Bilateral renal-nerve ablation resulted in a marked reduction in mean norepinephrine spillover from both kidneys: 47% (95% confidence interval) one month after treatment.

In a similar human trial where bilateral renal nerve ablation was performed in 70 patients, whole-body norepinephrine levels (i.e., a measure of “total” sympathetic activity), fell by nearly 50% after renal nerve ablation and measurement of muscle sympathetic nerve activity showed a drop of 66% over 6 months, further supporting the conclusion that total sympathetic dive was reduced by the renal denervation procedure in this patient group.

Full text: Click here
Patent 2024
Aftercare Catheter Ablation, Percutaneous Catheters Essential Hypertension Homo sapiens Human Body Kidney Muscle Denervation Muscle Tissue Nervousness Norepinephrine Obstetric Delivery Patients Post-Traumatic Stress Disorder Renal Artery Renal Circulation Technique, Dilution
A total of 354 patients with essential hypertension who were treated in the People’s Hospital of Qingyang City from July 2021 to March 2022 were enrolled. There were 188 males and 166 females of Han ethnicity. Their average age was (64.00 ± 10.52) years.
Publication 2023
Essential Hypertension Ethnicity Females Males Patients
Preoperative factors were collected, including age, sex, recent major cardiovascular procedure (within 3 months), coronary artery disease, cerebral vascular events, chronic lung disease, essential hypertension, dyslipidemia, liver cirrhosis, atrial fibrillation, type 2 diabetes mellitus, end-stage renal disease with dialysis (both hemodialysis and peritoneal dialysis), and regular use of antiplatelet or anticoagulant agents. The major cardiovascular procedures included coronary arterial bypass, coronary arterial angioplasty/stenting, cardiac valvular surgery, aortic surgery, and peripheral arterial surgery. Preoperative blood cell counts included white cell counts, differential counts (immature band form white cell) [15 (link)], platelet counts, the neutrophil-to-lymphocyte ratio (NLR) [16 (link)], and hemoglobin levels. Preoperative blood biochemistry results included serum levels of albumin, alanine aminotransferase (ALT), bilirubin, and creatinine. The coagulation test included the prothrombin time (PT) and was expressed by the international normalized ratio (INR). Preoperative shock status was defined as the requirement for vasopressors or inotropes. The types of AMI were determined by preoperative contrast CT scans.
Full text: Click here
Publication 2023
Angioplasty Angioplasty, Balloon, Coronary Anticoagulants Aorta Arteries Artery, Coronary Atrial Fibrillation Bilirubin BLOOD Cardiovascular System Cells Cerebrovascular Accident Coronary Arteriosclerosis Coronary Artery Bypass Surgery Creatinine D-Alanine Transaminase Diabetes Mellitus, Non-Insulin-Dependent Dialysis Disease, Chronic Dyslipidemias Essential Hypertension Hemodialysis Hemoglobin Inotropism International Normalized Ratio Kidney Failure, Chronic Leukocyte Count Liver Cirrhosis Lung Lung Diseases Lymphocyte Neutrophil Neutrophil Band Cells Operative Surgical Procedures Peritoneal Dialysis Platelet Counts, Blood Serum Albumin Shock Surgical Procedure, Cardiac Tests, Blood Coagulation Times, Prothrombin Vasoconstrictor Agents X-Ray Computed Tomography
The readmission was defined as unplanned readmission to the hospital due to any diagnosis within 30 days, 60 days, 90 days, and 180 days from index discharge. If there were more than one readmission, only the first readmission was counted. Over-weight and obesity was defined as BMI ≥ 25 kg/m2 (15 (link), 16 (link)). There was still lack of consensus on the definition of metabolic health status. However, many studies defined metabolic unhealthy status as presence of ≥2 metabolic risk factors (17 (link), 18 (link)). According to the Adult Treatment Panel III (ATP-III) criteria and the International Diabetes Federation (IDF) consensus (19 (link), 20 (link)), we defined metabolic risk factors including (1) hypertension: primary hypertension or secondary hypertension or undiagnosed elevated blood pressure; (2) dyslipidemia: high serum triglyceride (TGs) levels or high high-density lipoprotein (HDL)-cholesterol levels, etc.; (3) hyperglycemia: pre-diabetes or diabetes mellitus or other specific diabetes. Abdominal obesity was not included in the models because of the collinearity of waist circumference and BMI. Metabolically unhealthy status was defined as with two or more of the above metabolic risk factors. The codes used were listed in Supplementary Table 1. Based on the obesity and metabolic status, individuals were classified into four different phenotypes; (1) metabolically healthy non-obesity (MHNO); (2) metabolically unhealthy non-obesity (MUNO); (3) metabolically healthy obesity (MHO); and (4) metabolically unhealthy obesity (MUO). For 90-day analysis, based on combined metabolic risk factor type only, individuals were further divided into: (1) no metabolic risk factor; (2) only with hyperglycemia; (3) only with dyslipidemia; (4) only with hypertension. In addition, based on the number of combined metabolic risk factors, individuals were further divided into: (1) no metabolic risk factor; (2) one metabolic risk factor; (3) two metabolic risk factors; (4) three metabolic risk factors.
Full text: Click here
Publication 2023
Adult Blood Pressure Diabetes Mellitus Diagnosis Dyslipidemias Essential Hypertension High Blood Pressures High Density Lipoprotein Cholesterol Hyperglycemia Obesity Obesity, Metabolically Benign Patient Discharge Patient Readmission Phenotype Serum States, Prediabetic Triglycerides Waist Circumference
Eligible high-risk patients were aged at least 18 years, had ongoing COVID-19 confirmed by SARS-CoV-2 nasopharyngeal sample positivity using real-time polymerase chain reaction (RT-PCR) and antigenic testing, and possessed ≥ 1 predefined patient-level risk factor for disease progression at inclusion. Predefined patient-level risk factors were essential hypertension, obesity (body mass index > 25 kg/m2), chronic cardiovascular disease, chronic cerebrovascular disease, chronic pulmonary disease, chronic renal disease, chronic liver disease, diabetes mellitus, immunocompromised state, and active oncological and haematological malignancies. All eligible patients were included consecutively at COVID-19 diagnosis if they consented to receive remdesivir for a minimum of 3 days and promptly started after diagnosis ascertainment. No a priori exclusion criteria were used. COVID-19 severity was given according to the World Health Organisation (WHO) criteria (WHO 2022 ). After inclusion completion, the cohort was stratified into two subgroups according to active haematological malignancy as a comorbidity.
Full text: Click here
Publication 2023
Antigens Cardiovascular Diseases Cardiovascular System Chronic Kidney Diseases COVID 19 Diabetes Mellitus Diagnosis Disease, Chronic Disease Progression Essential Hypertension Hematologic Neoplasms Index, Body Mass Liver Liver Diseases Lung Lung Diseases Nasopharynx Neoplasms Obesity Patients Real-Time Polymerase Chain Reaction remdesivir Reverse Transcriptase Polymerase Chain Reaction SARS-CoV-2

Top products related to «Essential Hypertension»

Sourced in United States
The Symplicity Flex is a medical device designed for use in the treatment of hypertension. It is a catheter-based tool that is used to perform renal denervation, a procedure that targets the nerves surrounding the renal arteries to reduce blood pressure. The Symplicity Flex provides a minimally invasive approach to this treatment.
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
Sourced in United States
SPSS 13.0 is a statistical software package developed by IBM. It provides tools for data analysis, including descriptive statistics, regression analysis, and hypothesis testing. The software is designed to help users interpret and understand their data effectively.
Sourced in United States, Denmark, Austria, United Kingdom
Stata version 13 is a software package designed for data analysis, statistical modeling, and visualization. It provides a comprehensive set of tools for managing, analyzing, and presenting data. Stata 13 offers a wide range of statistical methods, including regression analysis, time-series analysis, and multilevel modeling, among others. The software is suitable for use in various fields, such as economics, social sciences, and medical research.
Sourced in United States
The HumanOmni1-Quad BeadChip is a high-throughput genotyping array designed by Illumina. It enables the simultaneous analysis of over 1 million genetic variants across the human genome.
Sourced in Japan
The Hitachi 7600-020 is an automatic biochemistry analyzer designed for the analysis of various clinical chemistry parameters in biological samples. The core function of this equipment is to perform automated biochemical tests and provide accurate and reliable results to support clinical decision-making.
Sourced in United States, United Kingdom, Japan, Germany, Austria, Belgium, France, Denmark
SPSS 24.0 is a statistical software package developed by IBM. It provides data management, analysis, and reporting capabilities. The software is designed to handle a wide range of data types and is commonly used for social science research, market research, and business analytics.
Sourced in Japan
The HEM-7220 is a digital blood pressure monitor designed for home use. It features an easy-to-read LCD display and automatic inflation and deflation of the cuff. The device is intended for measuring systolic and diastolic blood pressure, as well as pulse rate.
Sourced in United States
ALZET 1002 is a miniature osmotic pump designed for continuous, controlled delivery of substances in small laboratory animals. It delivers the substance at a pre-determined rate for up to 2 weeks. The pump is implantable and requires a small surgical procedure for placement.
Sourced in United States
The Beckman Access Immunoassay System is an automated platform designed for the analysis of various immunoassays. It utilizes chemiluminescent detection technology to provide quantitative results for a range of analytes.

More about "Essential Hypertension"

Essential hypertension, also known as primary hypertension or idiopathic hypertension, is a common medical condition characterized by persistently elevated blood pressure without an identifiable underlying cause.
It is a major risk factor for cardiovascular disease, stroke, and kidney damage.
Researchers can leverage advanced tools like PubCompare.ai to streamline their essential hypertension studies.
PubCompare.ai is an AI-powered platform that helps locate relevant protocols from literature, preprints, and patents, and provides AI-driven comparisons to identify the best research approaches.
By enhancing reproducibility and accuracy, PubCompare.ai can be the ultimate tool for your essential hypertension research needs.
In addition to PubCompare.ai, researchers may also utilize other statistical software and medical devices to support their essential hypertension studies.
These include Symplicity Flex for renal denervation procedures, SAS version 9.4 and SPSS 13.0 for data analysis, Stata version 13 for statistical modeling, HumanOmni1-Quad BeadChip for genome-wide association studies, 7600-020 automatic biochemistry analyzers for laboratory testing, SPSS 24.0 for advanced statistical analysis, HEM-7220 for home blood pressure monitoring, and ALZET 1002 for drug delivery in animal studies.
By incorporating these tools and techniques, researchers can optimize their essential hypertension research, leading to improved understanding, treatment, and management of this prevalent cardiovascular condition.